A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: A hoosier oncology group study

Kristen N. Ganjoo, Michael Robertson, William Fisher, Sin Ho Jung, John McClean, Sang Yoon Huh, Jose Bufill, Sheron Williams, Larry Cripe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m 2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61%) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume28
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

gemcitabine
Non-Hodgkin's Lymphoma
Proxy
B-Cell Chronic Lymphocytic Leukemia
Neutropenia
Hodgkin Disease
Lymphoma
Appointments and Schedules
Drug Therapy

Keywords

  • Gemcitabine
  • Low-grade lymphoma
  • Non-Hodgkin Lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas : A hoosier oncology group study. / Ganjoo, Kristen N.; Robertson, Michael; Fisher, William; Jung, Sin Ho; McClean, John; Huh, Sang Yoon; Bufill, Jose; Williams, Sheron; Cripe, Larry.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 28, No. 2, 04.2005, p. 169-172.

Research output: Contribution to journalArticle

@article{790e1566663f473583c4e7c5cc1a2534,
title = "A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: A hoosier oncology group study",
abstract = "Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m 2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61{\%}) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.",
keywords = "Gemcitabine, Low-grade lymphoma, Non-Hodgkin Lymphoma",
author = "Ganjoo, {Kristen N.} and Michael Robertson and William Fisher and Jung, {Sin Ho} and John McClean and Huh, {Sang Yoon} and Jose Bufill and Sheron Williams and Larry Cripe",
year = "2005",
month = "4",
doi = "10.1097/01.coc.0000144812.74663.d0",
language = "English",
volume = "28",
pages = "169--172",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas

T2 - A hoosier oncology group study

AU - Ganjoo, Kristen N.

AU - Robertson, Michael

AU - Fisher, William

AU - Jung, Sin Ho

AU - McClean, John

AU - Huh, Sang Yoon

AU - Bufill, Jose

AU - Williams, Sheron

AU - Cripe, Larry

PY - 2005/4

Y1 - 2005/4

N2 - Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m 2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61%) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.

AB - Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m 2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61%) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.

KW - Gemcitabine

KW - Low-grade lymphoma

KW - Non-Hodgkin Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=17044378079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044378079&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000144812.74663.d0

DO - 10.1097/01.coc.0000144812.74663.d0

M3 - Article

C2 - 15803012

AN - SCOPUS:17044378079

VL - 28

SP - 169

EP - 172

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -